Rheological factors in coronary heart disease;Rheologie und koronare herzkrankheit

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 50 SUPPL. 8, 2008, Pages

  Leschke, Matthias ^a  

^a KLINIKUM ESSLINGEN   (Germany)

Author keywords

Blood flow; Coronary artery disease; Fibrinogen; Rheology; Urokinase treatment

Indexed keywords

FIBRINOGEN; PLASMINOGEN; UROKINASE; VON WILLEBRAND FACTOR;

ANGINA PECTORIS; ARTERIOSCLEROSIS; BLOOD CLOT LYSIS; BLOOD RHEOLOGY; BLOOD VISCOSITY; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DNA SYNTHESIS; ERYTHROCYTE AGGREGATION; ERYTHROCYTE FRAGILITY; FIBRINOLYSIS; FIBROBLAST; HEMATOCRIT; HUMAN; MICROCIRCULATION; PATHOPHYSIOLOGY; REVIEW; TREATMENT INDICATION;

ANGINA PECTORIS; BLOOD VISCOSITY; CORONARY CIRCULATION; CORONARY DISEASE; CORONARY STENOSIS; ERYTHROCYTE AGGREGATION; FIBRINOGEN; HEMORHEOLOGY; HUMANS; SYNDROME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR RESISTANCE;

EID: 58049208223     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1100960     Document Type: Review

References (24)

1. Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522-23
2. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis 1993; 100: 1-12
3. Fahraeus R. Die Strömungsverhältnisse und die Verteilung der Blutzellen im Gefäßsystem. Klin Wochenschr 1928; 7: 100-106
4. Fibrinogen Studies' Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. JAMA 2005; 294: 1799-1809
5. Fuchs J, Weinberger I, Rotenberg Z et al. Plasma viscosity in ischemic heart disease. Am Heart J 1984; 108: 435-439
6. Kaul S, Jayaweera AR. Determinants of microvascular flow. Europ Heart J 2006; 27: 2227-2274
7. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol 2002; 39: 923-34
8. Leschke M, Blanke H, Stellwaag M et al. Hyperfibrinogenämie und pathologische Plasmaviskosität. Dtsch Med Wschr 1988; 113: 1175-1181
9. Leschke M, Höffken H, Schmidtsdorff A. Einfluß von Fenofibrat auf Fibrinogenkonzentration und Blutfluidität. Dtsch Med Wschr 1989; 114: 939-944
10. Leschke M, Strauer BE. Die Bedeutung Theologischer Mechanismen in der Atherogenese. Arzneim-Forsch/Drug Res 1990; 40: 356-62
11. Leschke M, Schoebel FC, Mecklenbeck W et al. Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial. J Am Coll Cardiol 1996; 27: 575-84
12. Leschke M, Schoebel FC, Strauer BE. Symptomatische therapierefraktäre Myokardischämie bei koronarer Herzkrankheit. Internist 1996; 37: 597-606
13. Leschke M, Klimek W, Jung F. Rheologische Determinanten von Endorganschäden. Internist 2003; 44: 853-863
14. Mahmud E, Cavendish JJ, Tsimikas S et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol 2007; 49: 2163-71
15. Rim SH, Leong-Poi H, Lindner JR et al. Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 2001; 104: 2705-2709
16. Schmid-Schönbein H. Myokardiale Mikrozirkulation. Wechselwirkung zwischen Vasomotorik und Fließeigenschaften des Blutes. Dtsch Med Wschr 1981; 106: 1483-1487
17. Schoebel FC, Leschke M, Stein D et al. Chronic-intermittent urokinase therapy in refractory angina pectoris. Fibrinolysis 1995; 9(suppl): 121-125
18. Schoebel FC, Leschke M, Strauer BE. Therapierefraktäre Angina pectoris. Dtsch Med Wschr 1995; 120: 301-307
19. Schoebel FC, Frazier H, Jessurun GAJ et al. Refractory angina pectoris in endstage coronary artery disease: Evolving therapeutic concepts. Am Heart J 1997; 134: 587-602
20. Schuff-Werner P, Schütz E, Seyde WC et al. Improved hemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin induced extracorporal precipitation. Eur J Clin Invest 1989; 19: 30-37
21. Sinning JM, Bickel C, Messow CM et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Europ Heart J 2006; 27: 2962-2968
22. Strauer BE. Koronare Mikrozirkulationsstörungen. Klin Wochenschr 1981; 59: 1125-1137
23. Strauer BE, Fatah-Moghadam A, Kment A et al. Use of plasmapheresis and immunosuppressive Therapy in Coronary microangiopathies. Bibl Haematol 1981; 47: 213-227
24. Stuart J. The acute phase reaction and haematological stress syndrome in vascular disease. Int J Microcirc Clin Exp 1984; 3: 257-262